Prolactinoma and Gestation: A Reality

Naliato, Erika Cesar de Oliveira; Vanni, Gabriel Neiva Mello; Melo, Rafaela Palhano Sifuentes; Violante, A

doi:10.21767/2471-9803.1000163

Cited by 2 publications

(4 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Women with prolactinoma using dopamine agonists and with normal PRL levels present restored gonadal function in 80–90% of cases. These drugs recover their fertility and can conceive, regardless of tumor size ( 17 ). Pituitary tumors are classified as microadenomas (<1 cm) versus macroadenomas (⪖1 cm) ( 2 ).…”

Section: Discussionmentioning

confidence: 99%

“…As reported, her treatment was irregular due to the clinical history of side effects from BRC, especially gastrointestinal effects. However, approximately one year after her diagnosis she became pregnant, leading to suspension of dopamine agonists as recommended by various authors ( 17 – 19 ).…”

Section: Discussionmentioning

confidence: 99%

“…The patient remained off medication for 11 years, which usually occurs in post-gestational periods in patients with prolactinoma ( 17 , 18 ). However, she underwent annual monitoring, and her dopamine agonists therapy was resumed (this time with CAB) when her prolactin levels began to increase, and she presented altered pituitary imaging.…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Binge Eating and Compulsive Buying During Cabergoline Treatment for Prolactinoma: A Case Report

Castro

Araujo

Botelho³

et al. 2022

Front. Psychiatry

View full text Add to dashboard Cite

Prolactinomas are the most prevalent functional pituitary adenomas. They are usually treated clinically with dopamine agonists. The most widely used and suitable drug is cabergoline (CAB), a specific D2 dopamine agonists. Patients in prolactinoma treatment with CAB commonly report physical side effects, but aberrant behavioral changes such as increased impulsivity have also been reported recently. We report the case of a 47-year-old Brazilian woman with prolactinoma that developed compulsive buying, binge eating, and hypersexuality after four years of CAB treatment. In her psychiatric evaluation, the patient scored high levels on the following scales: Compulsive Buying Scale (CBS), Binge Eating Scale (BES), and Barratt Impulsiveness Scale-11 (BIS11). She also reported financial problems and weight gain in addition to her social and clinical problems. Impulsivity disorders may appear with the use of CAB and other dopamine agonists. We suggest that more observational studies with a large patient sample and specific regular psychiatric evaluations during treatment are necessary for patients in use of CAB, especially those treated for several years.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Binge Eating and Compulsive Buying During Cabergoline Treatment for Prolactinoma: A Case Report

Castro

Araujo

Botelho³

et al. 2022

Front. Psychiatry

View full text Add to dashboard Cite

show abstract

“…22 It is worth mentioning that cabergoline is recommended for women, independent of their desire to conceive. 23 Follow-up for dopamine agonist treatment includes periodic PRL measurement to guide treatment intensity, achieve normal PRL levels and reverse hypogonadism, as well as magnetic resonance imaging (MRI) after 1 year (or after 3 months if the patient presents a macroadenoma, if PRL levels continue to rise while on dopamine agonist treatment, or if new symptoms occur). With careful clinical follow-up, therapy can be tapered off or even discontinued in patients treated with dopamine agonists for at least 2 years who no longer have elevated serum PRL or visible tumor remnants in an MRI.…”

Section: Introductionmentioning

confidence: 99%

Body self-image disturbances in women with prolactinoma

Pereira

Naliato

Moraes³

et al. 2020

Braz. J. Psychiatry

View full text Add to dashboard Cite

To evaluate body dissatisfaction and distorted body self-image in women with prolactinoma. Methods: Body dissatisfaction and distorted body self-image were evaluated in 80 women with prolactinoma. All patients were in menacme, 34% had normal body mass index (BMI), and 66% were overweight. Most patients (56.2%) had normal prolactin (PRL) levels and no hyperprolactinemia symptoms (52.5%). The Body Shape Questionnaire (BSQ) was used to assess the patients' dissatisfaction with and concern about their physical form, and the Stunkard Figure Rating Scale (FRS) was used to assess body dissatisfaction and distorted body self-image. The patients were divided according to PRL level (normal vs. elevated) and the presence or absence of prolactinoma symptoms. Results: The normal and elevated PRL groups had similar incidences of body dissatisfaction and distorted body self-image. However, symptomatic patients reported a higher incidence of dissatisfaction than asymptomatic patients. Distorted body self-image was less common among symptomatic patients. Conclusion: Symptomatic patients showed higher body dissatisfaction, but lower body self-image distortion. The presence of symptoms may have been responsible for increased body awareness. The perception of body shape could have triggered feelings of dissatisfaction compared to an ideal lean body. Therefore, a distorted body self-image might not necessarily result in body dissatisfaction in women with prolactinomas.

show abstract

Prolactinoma and Gestation: A Reality

Cited by 2 publications

References 7 publications

Binge Eating and Compulsive Buying During Cabergoline Treatment for Prolactinoma: A Case Report

Binge Eating and Compulsive Buying During Cabergoline Treatment for Prolactinoma: A Case Report

Body self-image disturbances in women with prolactinoma

Contact Info

Product

Resources

About